オクヤマ　リョウ   OKUYAMA Ryo   奥山 亮    所属   立命館アジア太平洋大学  国際経営学部    職種   教授
言語種別	英語
発行・発表の年月	2023/05
形態種別	学術論文
査読	査読あり
標題	Strengthening the Competitiveness of Japan’s Pharmaceutical Industry: Analysis of Country Differences in the Origin of New Drugs and Japan’s Highly Productive Firm.
執筆形態	単著
掲載誌名	Biological and Pharmaceutical Bulletin
掲載区分	国外
出版社・発行元	The Pharmaceutical Society of Japan
巻・号・頁	46(5),pp.718-724
総ページ数	7
担当区分	筆頭著者,責任著者
著者・共著者	Ryo Okuyama
概要	The author found that bio-ventures established in the 1990s and 2000s played a crucial role in creating new drugs approved by the FDA from 2017 to 2022 in regions outside of Japan. In contrast, in Japan, all approved drugs were created by old incumbent pharmaceutical companies, highlighting the urgent need to foster drug discovery start-ups in Japan. A case study of the Japanese company that created the largest number of FDA-approved drugs suggests that focused investment in modality technology development, strengthening collaboration with academia in biology, and the reutilizing small-molecule drug discovery capabilities are essential for improving drug discovery productivity.
DOI	https://doi.org/10.1248/bpb.b23-00107